Alzheimer’s Disease/Dementia News

A systematic review and meta-analysis of trial literature found that medications investigated for treatment of agitation in dementia demonstrated no significant effect on cognition, according to a poster presentation at CTAD.

Annovis Bio has been permitted by the Data and Safety Monitoring Board to continue its phase 2/3 trial of buntanetap, an oral protein inhibitor for moderate to mild Alzheimer’s disease, according to a company release.

In a cohort of older adults, the COVID-19 pandemic was a mitigating factor in self-perceived cognitive decline, the presence of which indicated a higher risk factor for worsening cognitive function in the year following the pandemic.

For early detection of Alzheimer’s disease in older adults, comorbidities remained strongly associated with mild cognitive impairment, but prediction decreased with age, according to a poster presentation at CTAD.

An artificial intelligence-based machine learning model that diagnosed cognitive impairment in Alzheimer’s disease extracted information more accurately than standard screening or human analysis, according to a poster presentation at CTAD.

Time-dependent worsening of cognition and function among a cohort of individuals with biomarker-proven Alzheimer’s disease or dementia was accurately detected by a composite neurocognitive measure.

A novel, eye-tracking metrics device aided in the detection of dementia risk in a small population of Colombian individuals with differing levels of education, according to a poster presented at CTAD.

Mounting evidence suggests that herpes simplex virus 1 may be associated with an increased risk for Alzheimer’s disease and dementia, according to a systematic review of published studies.

For clinicians who treat patients with Alzheimer’s disease, quantification of amyloid positron emission tomography was feasible and possessed a high degree of concordance with visual analysis, according to a presentation at CTAD.

Technology was found to be both easy to use and highly acceptable in a cohort of those with Alzheimer’s-related agitation and their caregivers, according to a poster presentation at CTAD.